Illumina Comments on Roche’s Unsolicited Tender Offer Extension
Illumina, Inc. has issued the following statement regarding Roche’s decision to extend its unsolicited tender offer to acquire all outstanding shares of Illumina for $44.50 in cash per common share:
“The extension by Roche was expected. An extremely low number of shares have been tendered, consistent with our view - and that of our stockholders - that Roche’s offer does not reflect Illumina’s unique leadership position, business performance and future prospects.
“We remain focused on continuing to develop breakthrough products that expand existing markets and create new ones. The potential of our industry is enormous, with major new markets emerging in medical diagnostics, reproductive health and cancer management.”